Arcadia Biosciences (RKDA) Announces First-Quarter 2021 Financial Results and Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Arcadia Biosciences (RKDA) Tops Q1 EPS by 41c, Revenues Miss
May 17, 2021 4:34 PM EDTArcadia Biosciences (NASDAQ: RKDA) reported Q1 EPS of $0.11, $0.41 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $828 thousand versus the consensus estimate of $850 thousand.
"With our acquisition of select assets of Lief Holdings, LLC and Live Zola,... More
